Virology institute launches Russia's second COVID-19 vaccine human trial

Virology institute launches Russia's second COVID-19 vaccine human trial

Virology institute launches Russia's second COVID-19 vaccine human trial

He likened the vaccine to Russia's 1957 launch of the world's first satellite, Sputnik 1. The Gamaleya Institute in Russian Federation, which carried out trials of its own experimental vaccine, is relying on scientific knowledge acquired six years ago in the fight against Ebola and the Middle East respiratory syndrome (Mers), a viral respiratory disease caused by a novel coronavirus, Mr Dmitriev said. We are indebted to the participants and investigators who now begin the work of the COVE study itself.

"There are also wide concerns the human testing of the vaccine is incomplete", the report highlighted.

Oxford University recently had announced satisfactory progress with the vaccine, making it one of the leading ones among the dozens of vaccine candidates being developed around the world.

Some 30,000 volunteers will be recruited at more than 120 sites worldwide. The second vaccine, being moved into advanced trials, targets the entire spike structure.

Russian developers will conduct the third phase of testing in parallel with registering the vaccine for approval in the first part of August.

"Moderna remains highly vigilant to potential cybersecurity threats, maintaining an internal team, external support services and good working relationships with outside authorities to continuously assess threats and protect our valuable information", company spokesman Ray Jordan said in a statement. That's the approach being taken in many other countries and by other companies.

"The Ministry of Health in Russian Federation is following all necessary strict procedures".

"This gives us confidence that we can test a single-shot vaccine in this epidemic and learn whether it has a protective effect in humans", Paul Stoffels, J&J's chief scientific officer, told Reuters in a telephone interview.

"A successful vaccine against Sars-Cov-2 could be used to prevent infection, disease and death in the whole population, with high-risk populations such as hospital workers and older adults prioritised to receive vaccination".

The EU executive also said at the meeting that it had approached vaccine makers about whether additional doses of influenza vaccine were available, according to the document.

Balram Bhargava, Director General of Indian Medical Research Institute (ICMR), talked about the four challenges that will arise after a safe and effective vaccine is developed.

The World Health Organization (WHO) has said that "this organism may be close wild-type and pathogenic, adapted and/or attenuated from wild-type with less or no pathogenicity, or genetically modified on some manner". Enrollment in the Calquence study is expected to finish by mid-August, with the first readout due in September, Jose Baselga, Astra's head of cancer research, said Monday in an interview. "We have made it clear that all tests on vaccines will have to meet regulatory standards and include all ethical review and strong data monitoring and safety boards", he said at the conference attended by top officials from the ICMR, the Departments of Biotechnology and the Health Ministry. Last week, the US government said it agreed to a $1.95 billion deal to buy 100 million doses of a vaccine from Pfizer Inc. and BioNTech SE if approved by regulators. Russian officials have denied the claims, and AstraZeneca said there's no evidence it's been hit.

Related news



[an error occurred while processing the directive]